This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

DiaDexus Appoints Dr. Robert Schott As Vice President Of Medical Affairs

Stocks in this article: DDXS

SOUTH SAN FRANCISCO, Calif., June 13, 2012 /PRNewswire/ -- diaDexus, Inc. (OTC QB: DDXS), a company focused on the development and commercialization of proprietary cardiovascular diagnostic products, today announced that Robert J. Schott, M.D., M.P.H., F.A.C.C., has been appointed to the position of vice president of medical affairs.  Dr. Schott brings 30 years of medical experience to diaDexus, the majority as a practicing cardiologist, which will be highly relevant as the company continues to expand the market awareness of both the PLAC® Test ELISA Kit and the PLAC® Test for Lp-PLA2 Activity, simple blood tests that aid in assessing risk for coronary heart disease (CHD), ischemic stroke and cardiovascular disease. Dr. Schott most recently served as medical director and the director of cardiometabolic research at the Profil Institute for Clinical Research.

"Dr. Schott is an important addition to our leadership team.  His depth of knowledge, experience and relationships in the cardiology field will accelerate development of physician education programs necessary to drive awareness of our PLAC® blood tests. These diagnostics have a remarkable ability to help uncover a hidden risk of heart attack and stroke," stated Brian E. Ward, Ph.D., chief executive officer of diaDexus. "Dr. Schott's expertise will be instrumental not only in working closely with clinicians but also in supporting our reimbursement initiatives in order to maximize the value of our product portfolio for shareholders."

Dr. Schott joins diaDexus from San Diego where he was director of cardiometabolic research at the Profil Institute for Clinical Research, which specializes in early phase clinical research in diabetes and cardiometabolic disease. Previously, Dr. Schott was the chairman of cardiology at Deborah Heart and Lung Center, and the vice president of medical affairs and chief of cardiology at Sutter Medical Center in Sacramento. Dr. Schott holds B.S., M.D. and M.P.H. degrees from the University of Michigan, where he trained in internal medicine.  He trained in cardiology at the Massachusetts General Hospital and was a Burgher Fellow at the Harvard Medical School.  He was previously affiliated with Berkeley Heart Labs, where he was the associate director of the Lipid Institute Medical Clinic and was also a research scientist at the Max Planck Institute for Experimental Cardiology in Bad Nauheim.

"I am very enthusiastic about joining diaDexus. I have used the PLAC test as a preventive cardiologist, and have long found this marker of vascular inflammation to be clinically useful in the effort to more fully characterize heart attack and stroke risk in the growing population of patients who are susceptible to vascular events," stated Dr. Schott. "The PLAC® Test ELISA kit is FDA-approved and is recognized as a test which is well-validated as a marker for the short-term risk of heart attack and stroke. As a cardiologist who has treated thousands of patients over the years, I very much look forward to increasing our awareness of all the available tools for the detection of diseases which are increasingly manageable, diseases that when undertreated frequently have consequences that are devastating."

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,805.41 +127.51 0.76%
S&P 500 1,964.58 +13.76 0.71%
NASDAQ 4,483.7150 +30.9230 0.69%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs